Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

NCT06796803 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

398

Enrollment

OTHER

Sponsor class

Conditions

Potentially Resectable Hepatocellular Carcinoma

Interventions

DRUG: camrelizumab combined with rivoceranib and HAIC
DRUG: camerlizumab + rivoceranib

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]